FDA NEWS

Amgen osteoporosis drug could face FDA scrutiny - Forbes
Amgen 's experimental osteoporosis drug denosumab could have difficulty gaining Food and Drug Administration approval in its initial try, due to a higher incidence of infections compared with placebo seen in some patients, according to an
Source: www.forbes.com

Could Korean Leader Learn from Controversies over U.S. Beef Imports? - BusinessWeek
At first blush, a delay in South Korea’s resumption of U.S. beef imports in the face of vociferous public protests may appear yet another instance of emotional nationalism in the way of a deal, which makes business sense. But although it certainly
Source: www.businessweek.com

Committee critical of FDA bonuses - Seattle Post Intelligencer
WASHINGTON -- A congressional review of bonuses paid to employees at the Food and Drug Administration showed many went to the highest-paid staff rather than to field inspectors. The chairman of the House committee that released the findings Thursday
Source: seattlepi.nwsource.com

UPDATE 2-UCB plans epilepsy drug launch in autumn, shares up - Reuters UK
BRUSSELS, June 27 (Reuters) - Shares in UCB SA (UCB.BR: Quote , Profile , Research ) jumped on Friday after the Belgian pharmaceutical group said it aimed to launch its new epilepsy drug Vimpat in the autumn following European Medicines Agency
Source: uk.reuters.com

FDA Boosts Bonuses Despite Ongoing Criticism From Hill - Washington Post
Resize Text The Food and Drug Administration increased bonuses to its employees by 29 percent in the past year, despite earlier objections from lawmakers. The FDA paid $35 million in staff incentives for the year ending April 12, up from $27.1
Source: www.washingtonpost.com

House committee criticizes FDA over bonuses - BusinessWeek
A review of bonuses paid to employees at the Food and Drug Administration showed many went to the agency's highest-paid staff rather than to the inspectors in the field, according to a review by the House Energy and Commerce Committee. Lawmakers were
Source: www.businessweek.com

Vanda falls as insomnia drug misses some goals - Forbes
While biotechnology company Vanda Pharmaceuticals Inc. said Thursday a late-stage trial for an insomnia drug met its goal, the drug failed to show a long-term benefit compared with placebo, sending shares tumbling. In afternoon trading, Vanda shares
Source: www.forbes.com

Death-linked obesity drug - Sunday Herald
AN ANTI-OBESITY drug implicated in the deaths of five people is being handed out to Scots in contravention of advice from medical authorities. Rimonabant - also known under the brand name Accomplia - has just been given the go-ahead for general use
Source: www.sundayherald.com